Nathaniel David

Last updated
Nathaniel David
Nathaniel David.jpg
Nathaniel David at the Hello Tomorrow Summit in Paris, 2016
Born
San Francisco, California, U.S.
Nationality American
Alma mater Harvard University, University of California, Berkeley
Known for Structural biology, Crystallography, Sustainable Energy
AwardsMIT Technology Review Young Innovators Under 35
Scientific career
Fields Biotechnology, Sustainable Energy
InstitutionsKythera Biopharmaceuticals, Sapphire Energy, Unity Biotechnology

Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx (acquired by Takeda Pharmaceutical Company), Achaogen (NASDAQ: AKAO), Kythera Biopharmaceuticals (NASDAQ: KYTH, acquired by Allergan), Sapphire Energy and Unity Biotechnology. [1] [2] [3] These companies have collectively raised more than $1.5 billion in financing. [2]

Biography

David earned an A.B. in Biology from Harvard University and a Ph.D. in Molecular and Cellular Biology from University of California, Berkeley. [4] He co-founded his first company, Syrrx, during the final year of his doctoral work at UC Berkeley. [4] Syrrx was the first company in the world to build a high-throughput structural biology ‘factory,’ using automation, nano-scale experiments, and crystallography to make the determination of atomic structures of proteins easier, faster, and cheaper. [5] [6]

In 2002, while at Syrrx, he was named to the MIT Technology Review TR35 as one of the top 35 innovators in the world under the age of 35. [7]

In 2005, Syrrx was acquired by Takeda, and the FDA-approved drug Nesina arose from Syrrx discovery efforts. [8] [9]

David left Syrrx to co-found Achaogen (NASDAQ: AKAO), an antibiotic company, and Kythera Biopharmaceticals (NASDAQ: KYTH). [1] [10] He served as Chief Science Officer of Kythera while the company created a now-FDA-approved injectable drug Kybella that triggers the selective destruction of fat cells. [11] [12] Kythera went public in October 2012 on the NASDAQ exchange under the ticker symbol KYTH, and was acquired by Allergan in 2015 for $2.1 billion. [13] [14]

Achaogen's antibiotic plazomicin is effective against multidrug-resistant infections of Enterobacteriaceae. [15] In 2016, plazomicin demonstrated noninferiority for urinary tract infections (UTIs) in a pivotal phase III trial against colistin, and against meropenem for complicated UTIs and acute pyelonephritis. [16] [15] The U.S. Food and Drug Administration (FDA) approved plazomicin for adults with complicated UTIs and limited or no alternative treatment options in 2018; it is now sold under the brand name Zemdri. [17] In April 2019, Achaogen declared bankrupt. [18]

In 2007, while still serving as Chief Science Officer at Kythera, David co-founded Sapphire Energy, a company with a mission to develop renewable, algae-derived transportation fuels that are 100% compliant with the existing energy infrastructure. [19] In 2010, the company began construction of the world's first commercial algal bio-refinery, a project that was awarded more than $100 million in federal funding. [20] [21]

In 2011, David co-founded Unity Biotechnology (NASDAQ: UBX), [22] a company dedicated to lengthening human healthspan by selectively clearing senescent cells from the body. [1] [23] [24] [25] UNITY is creating medicines that target multiple diseases of aging. [1] David is currently the President of Unity Biotechnology. [22] [26]

Related Research Articles

ImClone Systems Incorporated was a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey, and its research headquarters in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully-owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company.

Genentech, Inc., is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, near Oxford, England.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.

<span class="mw-page-title-main">ViroPharma</span>

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.

<span class="mw-page-title-main">Amylin Pharmaceuticals</span> Biopharmaceutical company

Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.

Mentor Worldwide LLC is an American company that supplies surgical aesthetics products to plastic surgeons. The company is based in Santa Barbara, California. It produces one of two silicone gel breast implants. Titled MemoryGel, the product was approved by the U.S. Food and Drug Administration (FDA) on November 17, 2006. The other FDA-approved products are developed by competitors Allergan and Sientra. Mentor also produces a range of lipoplasty equipment for liposuction procedures as well as a Niacin-based skincare product line called NIA 24.

<span class="mw-page-title-main">ARIAD Pharmaceuticals</span> Defunct oncology company

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.

<span class="mw-page-title-main">Plazomicin</span>

Plazomicin, sold under the brand name Zemdri, is an aminoglycoside antibiotic used to treat complicated urinary tract infections. As of 2019 it is recommended only for those in whom alternatives are not an option. It is given by injection into a vein.

<span class="mw-page-title-main">Eravacycline</span> Chemical compound

Eravacycline is a synthetic halogenated tetracycline class antibiotic by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) were recently completed with mixed results. Eravacycline was granted fast track designation by the FDA and is currently available in USA.

<span class="mw-page-title-main">Novavax</span> American biotechnology company

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.

<span class="mw-page-title-main">Arbutus Biopharma</span> Canadian Bio Tech Company

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

<span class="mw-page-title-main">Ceftazidime/avibactam</span>

Ceftazidime/avibactam, sold under the brand name Avycaz among others, is a fixed-dose combination medication composed of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. It is used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia. It is only recommended when other options are not appropriate. It is given by injection into a vein.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

<span class="mw-page-title-main">Cefiderocol</span>

Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available. It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. It is given by injection into a vein.

Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections. It is administered via intravenous injection.

Jacques Ravel is an American microbiologist and professor, currently serving as Director at the Institute for Genome Sciences and Professor of Microbiology and Immunology at the University of Maryland School of Medicine. His academic work focuses on the dynamic between microbiome and women's health, and has included research on the role of the vaginal microbiome in protecting against infections, currently explored through LUCA Biologics as part of Seed. Ravel is currently director of the Collaborative Research Center on Sexually Transmitted Diseases, exploring the 'connection between human genetic variation, sexually transmitted infections, and the functions of the vaginal microbiome', and is part of the White House's Human Microbiome Project.

References

  1. 1 2 3 4 "Unity Bio Wants To "Lengthen Health Span," But 1st Goals More Modest | Xconomy". Xconomy. 3 February 2016. Retrieved 2016-03-09.
  2. 1 2 "Buck Institute launches Unity Biotechnology startup". The North Bay Business Journal. 3 February 2016. Retrieved 2016-03-09.
  3. ↑ Runge, Wolfgang (2014). Technology Entrepreneurship : A Treatise on Entrepreneurs and Entrepreneurship for and in Technology Ventures. Vol 2. KIT Scientific Publishing. p. 1032. ISBN   978-3-7315-0107-7.
  4. 1 2 "Biotech on brink of breakthroughs". SFGate. 22 February 2004. Retrieved 2016-03-09.
  5. ↑ Pollack, Andrew (2000-07-04). "Analyzing Proteins With X-Rays, Crystals and Some Luck". The New York Times. ISSN   0362-4331 . Retrieved 2016-03-09.
  6. ↑ Pollack, Andrew (2000-07-04). "The Next Chapter in the Book of Life Is Written in the Proteins". The New York Times. ISSN   0362-4331 . Retrieved 2016-03-09.
  7. ↑ "Innovator Under 35: Nathaniel David, 33". MIT Technology Review. Retrieved 2016-03-09.
  8. ↑ Pollack, Andrew (2005-04-20). "Some in Biotech Prefer an Acquisition to an I.P.O." The New York Times. ISSN   0362-4331 . Retrieved 2016-03-09.
  9. ↑ Parsa, Kishore Vl; Pal, Manojit (2011-08-01). "Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview". Expert Opinion on Drug Discovery. 6 (8): 855–869. doi:10.1517/17460441.2011.588695. ISSN   1746-045X. PMID   22651127. S2CID   24271265.
  10. ↑ "Emerging from Stealth Mode to Prevent Diseases of Aging Unity Biotechnology to Double Hiring in Bay Area". www.biospace.com. Retrieved 2016-03-09.
  11. ↑ "Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging". FierceBiotech. Retrieved 2016-03-09.
  12. ↑ "FDA approves treatment for fat below the chin" (Press release). U.S. Food and Drug Administration. April 29, 2015. Archived from the original on 2015-05-01. Retrieved 2016-03-09.
  13. ↑ Sachetta, Ryan. "Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion". Bloomberg.com. Retrieved 2016-03-09.
  14. ↑ "Top 10 biotech IPOs of 2012". FierceBiotech. Retrieved 2016-03-09.
  15. 1 2 Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP, et al. (EPIC Study Group) (February 21, 2019). "Once-Daily Plazomicin for Complicated Urinary Tract Infections". New England Journal of Medicine . 380 (8): 729–740. doi: 10.1056/NEJMoa1801467 . PMID   30786187.
  16. ↑ "Plazomicin Succeeds in Two Pivotal Phase 3 Studies". P&T Community. MediMedia. December 12, 2016. Retrieved 10 October 2019.
  17. ↑ "ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)". Achaogen. June 26, 2018. Retrieved 10 October 2019.
  18. ↑ Jacobs, Andrew (25 December 2019). "Crisis Looms in Antibiotics as Drug Makers Go Bankrupt". The New York Times. Retrieved 23 November 2022.
  19. ↑ Hsu, Tiffany (2009-10-04). "Using algae to make fuels, he's thinking beyond pond scum". Los Angeles Times. ISSN   0458-3035 . Retrieved 2016-03-09.
  20. ↑ "Sapphire Energy: Biofuels Digest's 2014 5-Minute Guide : Biofuels Digest". www.biofuelsdigest.com. Retrieved 2016-03-09.
  21. ↑ Pollack, Andrew (2010-07-26). "Exploring Algae as Fuel". The New York Times. ISSN   0362-4331 . Retrieved 2016-03-09.
  22. 1 2 "Unity SEC S-1 Form". April 5, 2018. Retrieved 2018-11-14– via sec.gov.
  23. ↑ "Mayo Clinic Taps Silicon Valley to Help People Age Gracefully". Fortune. Retrieved 2016-03-09.
  24. ↑ Yong, Ed (3 February 2016). "Clearing the Body's Retired Cells Slows Aging and Extends Life". The Atlantic. Retrieved 2016-03-09.
  25. ↑ "Boosting Life Span By Clearing Out Cellular Clutter". NPR.org. Retrieved 2016-03-09.
  26. ↑ "New Anti-Aging Startup Hopes To Clear Out The Body's Retired Cells". Fast Company. 3 February 2016. Retrieved 2016-03-09.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.